These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38320355)

  • 1. Ferritin-binding and ubiquitination-modified mRNA vaccines induce potent immune responses and protective efficacy against SARS-CoV-2.
    Yu T; Zhang C; Xing J; Zhang T; Xu Z; Di Y; Yang S; Jiang R; Tang J; Zhuang X; Jin N; Tian M
    Int Immunopharmacol; 2024 Mar; 129():111630. PubMed ID: 38320355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
    Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
    Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoparticle Vaccines Based on the Receptor Binding Domain (RBD) and Heptad Repeat (HR) of SARS-CoV-2 Elicit Robust Protective Immune Responses.
    Ma X; Zou F; Yu F; Li R; Yuan Y; Zhang Y; Zhang X; Deng J; Chen T; Song Z; Qiao Y; Zhan Y; Liu J; Zhang J; Zhang X; Peng Z; Li Y; Lin Y; Liang L; Wang G; Chen Y; Chen Q; Pan T; He X; Zhang H
    Immunity; 2020 Dec; 53(6):1315-1330.e9. PubMed ID: 33275896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced mucosal immune responses and reduced viral load in the respiratory tract of ferrets to intranasal lipid nanoparticle-based SARS-CoV-2 proteins and mRNA vaccines.
    Boley PA; Lee CM; Schrock J; Yadav KK; Patil V; Suresh R; Lu S; Feng MM; Hanson J; Channappanavar R; Kenney SP; Renukaradhya GJ
    J Nanobiotechnology; 2023 Feb; 21(1):60. PubMed ID: 36814238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
    Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
    Elife; 2022 Aug; 11():. PubMed ID: 36004719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humoral and Cellular Immune Responses to Vector, Mix-and-Match, or mRNA Vaccines against SARS-CoV-2 and the Relationship between the Two Immune Responses.
    Nam M; Yun SG; Kim SW; Kim CG; Cha JH; Lee C; Kang S; Park SG; Kim SB; Lee KB; Chung YS; Nam MH; Lee CK; Cho Y
    Microbiol Spectr; 2022 Aug; 10(4):e0249521. PubMed ID: 35946811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant.
    Zang J; Yin Y; Xu S; Qiao W; Liu Q; Lavillette D; Zhang C; Wang H; Huang Z
    Front Immunol; 2022; 13():908478. PubMed ID: 35844601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Methyltransferase-Defective Vesicular Stomatitis Virus-Based SARS-CoV-2 Vaccine Candidate Provides Complete Protection against SARS-CoV-2 Infection in Hamsters.
    Lu M; Zhang Y; Dravid P; Li A; Zeng C; Kc M; Trivedi S; Sharma H; Chaiwatpongsakorn S; Zani A; Kenney A; Cai C; Ye C; Liang X; Qiu J; Martinez-Sobrido L; Yount JS; Boyaka PN; Liu SL; Peeples ME; Kapoor A; Li J
    J Virol; 2021 Sep; 95(20):e0059221. PubMed ID: 34379509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intranasal SARS-CoV-2 RBD decorated nanoparticle vaccine enhances viral clearance in the Syrian hamster model.
    Patel DR; Minns AM; Sim DG; Field CJ; Kerr AE; Heinly TA; Luley EH; Rossi RM; Bator CM; Moustafa IM; Norton EB; Hafenstein SL; Lindner SE; Sutton TC
    Microbiol Spectr; 2024 Mar; 12(3):e0499822. PubMed ID: 38334387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bacteria-enabled oral delivery of a replicon-based mRNA vaccine candidate protects against ancestral and delta variant SARS-CoV-2.
    Jawalagatti V; Kirthika P; Hewawaduge C; Yang MS; Park JY; Oh B; Lee JH
    Mol Ther; 2022 May; 30(5):1926-1940. PubMed ID: 35123065
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of novel DNA vaccines encoding receptor-binding domain (RBD) dimer-Fc fusing antigens derived from different SARS-CoV-2 variants of concern.
    Zhang T; Wang Z; Yang J; Xu X
    J Med Virol; 2023 Feb; 95(2):e28563. PubMed ID: 36755368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection.
    Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Cordón PJ; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2022; 13():995235. PubMed ID: 36172368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protection.
    Konrath KM; Liaw K; Wu Y; Zhu X; Walker SN; Xu Z; Schultheis K; Chokkalingam N; Chawla H; Du J; Tursi NJ; Moore A; Adolf-Bryfogle J; Purwar M; Reuschel EL; Frase D; Sullivan M; Fry B; Maricic I; Andrade VM; Iffland C; Crispin M; Broderick KE; Humeau LMPF; Patel A; Smith TRF; Pallesen J; Weiner DB; Kulp DW
    Cell Rep; 2022 Feb; 38(5):110318. PubMed ID: 35090597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Self-assembled ferritin-based nanoparticles elicit a robust broad-spectrum protective immune response against SARS-CoV-2 variants.
    Wang W; Meng X; Cui H; Zhang C; Wang S; Feng N; Zhao Y; Wang T; Yan F; Xia X
    Int J Biol Macromol; 2024 Apr; 264(Pt 2):130820. PubMed ID: 38484812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An intranasal vaccine comprising SARS-CoV-2 spike receptor-binding domain protein entrapped in mannose-conjugated chitosan nanoparticle provides protection in hamsters.
    Tabynov K; Solomadin M; Turebekov N; Babayeva M; Fomin G; Yadagiri G; Renu S; Yerubayev T; Petrovsky N; Renukaradhya GJ; Tabynov K
    Sci Rep; 2023 Jul; 13(1):12115. PubMed ID: 37495639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intranasal VLP-RBD vaccine adjuvanted with BECC470 confers immunity against Delta SARS-CoV-2 challenge in K18-hACE2-mice.
    Lee KS; Rader NA; Miller-Stump OA; Cooper M; Wong TY; Shahrier Amin M; Barbier M; Bevere JR; Ernst RK; Heath Damron F
    Vaccine; 2023 Jul; 41(34):5003-5017. PubMed ID: 37407405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Influence of Adjuvant Type on the Immunogenicity of RBD/N Cocktail Antigens as a Vaccine Candidate against SARS-CoV-2 Virus.
    Brzuska G; Zimna M; Baranska K; Szewczyk B; Strakova P; Ruzek D; Krol E
    Microbiol Spectr; 2023 Jun; 11(3):e0256422. PubMed ID: 37199661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal immunization with the recombinant measles virus encoding the spike protein of SARS-CoV-2 confers protective immunity against COVID-19 in hamsters.
    Park SI; Park S; Lee K; Kwak HW; Kim YK; Park HJ; Bang YJ; Kim JY; Kim D; Seo KW; Lee SJ; Kim H; Kim Y; Kim DH; Park HJ; Jung SY; Ga E; Hwang J; Na W; Hong SH; Lee SM; Nam JH
    Vaccine; 2024 Jan; 42(2):69-74. PubMed ID: 38097457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MERS-CoV RBD-mRNA vaccine induces potent and broadly neutralizing antibodies with protection against MERS-CoV infection.
    Tai W; Zheng J; Zhang X; Shi J; Wang G; Guan X; Zhu J; Perlman S; Du L
    Virus Res; 2023 Sep; 334():199156. PubMed ID: 37336390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.